Unlimited Access. Try it Today! Your First 10 Days Always $0.99


Human Genome Sciences Inc.
Glaxo anti-cancer cocktail gets regulatory approval
Glaxo anti-cancer cocktail gets regulatory approval

After her melanoma, Cheryl Stratos is mostly back to a normal life, running a business and driving her teenage son to weekend events, but there are reminders that it could all come back: The sores all over her body, the high fevers, the hair loss -- even the possibility of a suddenly shortened life. For Stratos, of Virginia, and others who have benefitted from a class of revolutionary anti-cancer drugs known as BRAF mutation inhibitors, another tool in the fight against relapse has just been sharpened: Drug maker GlaxoSmithKline received FDA approval Wednesday for a new cocktail that includes a BRAF-targeting component. The London company, which purchased Rockville-based Human Genome...